Two highly selective RET tyrosine kinase inhibitors (TKIs), namely selpercatinib (LOX-292) and pralsetinib (Blue-667), had been approved by the FDA for RET-rearranged NSCLC. Here, RET is linked to non-small cell lung carcinoma.